SIOUX FALLS, S.D., May 1, 2012 /PRNewswire/ -- pharmaCline's Diabecline® antibiotic ointment (SSPT® Tetracycline) received the Bronze Award for 2012 Best New Pharmaceutical Product at the 25th Annual Edison Awards in New York City. pharmaCline joined some of the world's most well known corporations at the New York Academy of Sciences, which hosted the Edison Awards Innovation Showcase and Forum. The subsequent Awards Gala event acknowledged the hard work, innovation and commitment of all of the 2012 Edison Award winners.
"As the pace of innovation quickens and the 'race to next' becomes ever more competitive, it's increasingly important to take a moment out of our hectic lives to recognize excellence in innovation and greatness in the teams of innovators who make our future. We are honored to present pharmaCline, and its Diabecline antibiotic ointment, with an Edison Award as one of the leading innovators of today and tomorrow," says Thomas Stat, 2012 Edison Awards Steering Committee Chairman.
The Edison Award is one of the highest accolades a company can receive in the name of innovation and business. Edison's inventions, new product development methods and innovative achievements garnered 1,093 U.S. patents and made him a household name around the world.
"Thomas Edison is an American hero who has shaped our modern era," said pharmaCline CEO Steve Keough. "We are honored and humbled to receive this Award."
Diabecline antibiotic ointment utilizes pharmaCline's innovative Site Specific Penetration Technology™ (SSPT Tetracycline) to provide a solution to antibiotic resistance. Antibiotic resistance is a world-wide medical emergency recognized by the World Health Organization as a serious threat to the effectiveness of modern medicine.
Dr. Margaret Chan, Director General of the World Health Organization, said, "At a time of multiple calamities in the world, we cannot allow the loss of essential antimicrobials, essential cures for many millions of people, to become the next global crisis."
pharmaCline's SVP for Sales and Marketing, Sam Michini, said, "Our innovation was to go back in history and find the most widely tolerated antibiotic that kills a broad spectrum of bacteria, and to develop a safe and effective ointment delivery system that allows penetration through the pathogen's cell walls."
This efficient delivery of the drug to the nucleus of the bacteria results in exceptional kill capabilities against the most prevalent bacterial pathogens. The ointment also has moisture reducing properties that further prevent the development of resistance.
Thomas Edison is credited with going beyond technology and finding solutions to problems. pharmaCline is committed to finding solutions to difficult problems, such as antibiotic resistance. pharmaCline believes that many "old and proven solutions" can be retooled for re-use.
"By pairing innovative technologies with other proven products, or creating our own products, we move beyond theory to solution," said Michini. "This requires intentional development tied to the real challenges in our world."
pharmaCline® is an innovative technology and pharmaceutical company that has developed a proprietary drug delivery technology called Site Specific Penetration Technology™. Using this technology, pharmaCline has created a game-changing product line of topical hypoallergenic antimicrobial drugs. pharmaCline's new products provide an effective solution to the antibiotic resistance crisis worldwide.
About the Edison Awards
The Edison Awards are among the most prestigious accolades honoring excellence in new product and service development, marketing, human-centered design and innovation. Unique to the world of award programs, the Edison Awards are focused on the innovators as much as the innovations. Award winners represent "game changing" products, services and excellence in the leadership of innovation around four criteria: concept, value, delivery and impact.
Copyright©2010 PR Newswire.
All rights reserved